246 related articles for article (PubMed ID: 31964219)
21. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
22. Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.
Hori H; Kudoh T; Nishimura S; Oda M; Yoshida M; Hara J; Tawa A; Usami I; Tanizawa A; Yumura-Yagi K; Kato K; Kobayashi R; Komada Y; Matsuo K; Horibe K;
Int J Clin Oncol; 2017 Apr; 22(2):387-396. PubMed ID: 27858183
[TBL] [Abstract][Full Text] [Related]
23. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
24. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of early-onset cardiotoxic effects of anthracyclines used during the treatment of childhood acute lymphoblastic leukemia by speckle-tracking echocardiography.
Arman Bilir Ö; Çetin İİ; Kaçar D; Aker CB; Özbek NY; Yaralı N
Anatol J Cardiol; 2022 Jan; 26(1):57-62. PubMed ID: 34927587
[TBL] [Abstract][Full Text] [Related]
26. [Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Ostański M; Sońta-Jakimczyk D
Wiad Lek; 2002; 55(3-4):164-73. PubMed ID: 12182001
[TBL] [Abstract][Full Text] [Related]
27. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
[TBL] [Abstract][Full Text] [Related]
28. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
de Matos Neto RP; Petrilli AS; Silva CM; Campos Filho O; Oporto VM; Gomes Lde F; Paiva MG; Carvalho AC; Moisés VA
Arq Bras Cardiol; 2006 Dec; 87(6):763-71. PubMed ID: 17262115
[TBL] [Abstract][Full Text] [Related]
29. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
30. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
31. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
[TBL] [Abstract][Full Text] [Related]
32. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
33. Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
Gardner RA; Thomson B; Hawkins DS
Pediatr Blood Cancer; 2013 Feb; 60(2):338-9. PubMed ID: 23015453
[No Abstract] [Full Text] [Related]
34. Strain echocardiography in early detection of Doxorubicin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
Al-Biltagi M; Abd Rab Elrasoul Tolba O; El-Shanshory MR; Abd El-Aziz El-Shitany N; El-Sayed El-Hawary E
ISRN Pediatr; 2012; 2012():870549. PubMed ID: 22518327
[TBL] [Abstract][Full Text] [Related]
35. Cardiorespiratory status after treatment for acute lymphoblastic leukemia.
Turner-Gomes SO; Lands LC; Halton J; Hanning RM; Heigenhauser GJ; Pai M; Barr R
Med Pediatr Oncol; 1996 Mar; 26(3):160-5. PubMed ID: 8544797
[TBL] [Abstract][Full Text] [Related]
36. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
[TBL] [Abstract][Full Text] [Related]
38. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
39. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
[TBL] [Abstract][Full Text] [Related]
40. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
